Replies to post #6601 on ANI Pharmaceuticals (ANIP)

[Just the facts maam]

Smile86, I don't know where the rape talk is coming from.

In the past the CEO would provide updates on Libigel when requested. Now investor relations responds with "I'm afraid I cannot comment on the status of Libigel ".

Given the yet to be disclosed CV benefits, additional Breast Cancer reduction discoveries, three new patent applications, the trademark being allowed to expire without a new name being submitted to replace it and pulling the Libigel licensing opportunity from the Deals.bio website all points to ANI entering a Quiet Period with respect to Libigel.

During a Quiet Period, a publicly listed company cannot make any announcements about anything that could cause a normal investor to change their position on the company's stock. Normally, that means the company does not discuss any of the following:

New deals or wins signed in that current quarter. Announcements about previously sold implementations going live are allowed but must be explicitly described as such.
Management changes
Progress against company goals
Major product or service announcements
Major partnership announcements

Quiet Period

Incidentally, when I was speaking to the Abbvie employee, and rhymed off the following potential indications.
- HSDD $2-$3 billion revenue just by replacing off label and compounded prescriptions presently being issued later and potentially doubling when an FDA approved product hits the market.
- 70% reduction in cardiovascular events most likely targeting Hypertension and Dyslipidemia suffers
- Breast cancer risk reduction
- Cognitive Function improvement- Ani is sitting positive phase 2 data justifying phase 3 trial.

The 25 + year Abbott/Abbvie employee, who was unaware of Libigel,stated that the product would be a franchise unto itself with the potential to surpass Humira peak sale numbers, globally, and can't see them letting another company get a hold of it.

JMHO.